139 related articles for article (PubMed ID: 15044223)
1. Side effects of antituberculosis drugs.
Mohan A; Sharma SK
Am J Respir Crit Care Med; 2004 Apr; 169(7):882-3. PubMed ID: 15044223
[No Abstract] [Full Text] [Related]
2. Hepatotoxicity after a short course of low-dose pyrazinamide.
al Sarraf KA; Michielsen PP; Hauben EI; Lefebure A; Ramon AM; Van Marck EA; Pelckmans PA
Acta Gastroenterol Belg; 1996; 59(4):251-3. PubMed ID: 9085628
[TBL] [Abstract][Full Text] [Related]
3. [DRUG-INDUCED LIVER INJURY AND PYRAZINAMIDE USE].
Horita N; Miyazawa N
Kekkaku; 2015 Mar; 90(3):401-5. PubMed ID: 26477109
[TBL] [Abstract][Full Text] [Related]
4. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Ijaz K; McElroy PD; Navin TR
Clin Infect Dis; 2004 Jul; 39(2):289. PubMed ID: 15307044
[No Abstract] [Full Text] [Related]
5. [Clinically apparent liver damage during brief tuberculosis therapy].
Estay S; Armas Merino R; Vega C; Soto JR
Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
[No Abstract] [Full Text] [Related]
6. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
Burman WJ; Reves RR
Am J Respir Crit Care Med; 2001 Oct; 164(7):1112-3. PubMed ID: 11673194
[No Abstract] [Full Text] [Related]
7. [Hepatitis of prolonged development induced by various tuberculostatic drugs].
Brincourt J; Teyssier L
Rev Tuberc Pneumol (Paris); 1968; 32(6):831-8. PubMed ID: 5743631
[No Abstract] [Full Text] [Related]
8. [Liver injury under tuberculostatic treatment].
Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
[TBL] [Abstract][Full Text] [Related]
9. Antituberculosis drugs and hepatotoxicity.
Sharma SK
Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
[No Abstract] [Full Text] [Related]
10. Drugs for tuberculosis.
Med Lett Drugs Ther; 1988 Apr; 30(763):43-4. PubMed ID: 3352531
[No Abstract] [Full Text] [Related]
11. [First-time standard setting for therapy of pulmonary tuberculosis after revision of the Medical Treatment Standard--special reference to results of questionnaire survey on reality of early stage short-term PZA therapy and occurrence of the adverse effects].
Kekkaku; 1997 Nov; 72(11):639-42. PubMed ID: 9463114
[No Abstract] [Full Text] [Related]
12. [Agranulocytosis and toxic hepatic dystrophy during treatment with tuberculostatic drugs].
Rabina EV; Semichastnova AG; Golubiatnikova GA
Arkh Patol; 1972; 34(8):75-7. PubMed ID: 4345581
[No Abstract] [Full Text] [Related]
13. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
Vu D; Macdonald L
CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
[No Abstract] [Full Text] [Related]
14. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
[No Abstract] [Full Text] [Related]
15. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
[TBL] [Abstract][Full Text] [Related]
16. Pyrazinamide-induced anaphylaxis: diagnosed by skin test and successful desensitization.
Bavbek S; Yılmaz I; Aydın Ö; Ozdemir SK
Int Arch Allergy Immunol; 2012; 157(2):209-12. PubMed ID: 21986254
[TBL] [Abstract][Full Text] [Related]
17. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.
Younossian AB; Rochat T; Ketterer JP; Wacker J; Janssens JP
Eur Respir J; 2005 Sep; 26(3):462-4. PubMed ID: 16135729
[TBL] [Abstract][Full Text] [Related]
18. [Comprehensive view of hepatitis and the other reactions secondary to antituberculosis chemotherapy].
Girling DJ
Bull Int Union Tuberc; 1980; 55(1-2):9-13. PubMed ID: 7214064
[No Abstract] [Full Text] [Related]
19. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
Ridzon R; Meador J; Maxwell R; Higgins K; Weismuller P; Onorato IM
Clin Infect Dis; 1997 Jun; 24(6):1264-5. PubMed ID: 9195099
[No Abstract] [Full Text] [Related]
20. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
